Morgan Stanley Assumes Coverage on Boston Scientific (BSX) with an Overweight
More News related to BSX
- Boston Scientific Announces Sponsorship of World Diabetes Day Campaign 2009
- Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress
- Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan
- Boston Scientific (BSX) Announces Agreement with DoJ on Investigation of Guidant; Updates FY09 Outlook
- Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant
More News related to New Coverage
- Morgan Stanley Initiates Coverage on Williams Companies (WMB) with an Overweight
- Morgan Stanley Starts ONEOK (OKE) at Underweight, $40 Price Target
- Broadpoint.Amtech Initiates Coverage on Willbros Group (WG) with a Buy; Leading North American Pipeline Contractor
- Miller Tabak Initiates Coverage on Oclaro (OCLR) with a Buy
- Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
Morgan Stanley assumes coverage on Boston Scientific (NYSE: BSX) with an Overweight.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a b range of interventional medical specialties, including interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, oncology, endoscope, urology, gynecology and neuromodulation.
Related Categories
New CoverageStocks Mentioned
+0.11Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
